BioMarin Pharmaceutical | BMRN - PE Price to Earnings


BioMarin Pharmaceutical reported $15.13 in PE Price to Earnings for its fiscal quarter ending in June of 2025.



Financials
Stock Price USD
Assets USD 7.46B
Cash and Equivalent USD 1.21B
Cost of Sales USD 154.94M
Current Assets USD 3.81B
Current Liabilities USD 684.25M
Debt USD 603.87M
EBIT USD 276.89M
EBITDA USD 295.45M
Employees 3.04K
EPS Earnings Per Share USD 1.44
Equity Capital and Reserves USD 6.03B
Gross Profit on Sales USD 670.47M
Interest Expense on Debt USD 2.68M
Interest Income USD 18.83M
Loan Capital USD 596.16M
Market Capitalization USD 10.75B
Net Income USD 240.53M
Operating Expenses USD 548.52M
Operating Profit USD 276.89M
Ordinary Share Capital USD 192M
PE Price to Earnings USD 15.13
Pre-Tax Profit USD 297.87M
Sales Revenues USD 825M
Selling and Administration Expenses USD 232.28M
Stock USD 1.34B
Trade Creditors USD 684.25M
Trade Debtors USD 855.86M

Pe Change Date
Acadia Pharmaceuticals USD 16.19 4.11 Jun/2025
Agios Pharmaceuticals USD 2.88 0.36 Jun/2025
Amgen USD 12.51 28.7 Jun/2025
Bayer EUR 6.61 1.6 Jun/2025
Biogen USD 12.41 0.17 Jun/2025
BioMarin Pharmaceutical USD 15.13 7.26 Jun/2025
Gilead Sciences USD 15.39 279.48 Jun/2025
Incyte USD 14.77 134.3 Jun/2025
Ionis Pharmaceuticals USD 396.15 79.28 Sep/2022
Moderna USD 27.22 14.51 Jun/2023
Neurocrine Biosciences USD 42.61 5.9 Jun/2025
PTC Therapeutics USD 6.47 0.7 Jun/2025
Regeneron Pharmaceuticals USD 13.35 3.19 Jun/2025
Roche Holding CHF 19.32 1.87 Jun/2024
Sanofi EUR 16.51 9.31 Jun/2025
Sarepta Therapeutics USD 27.27 0 Jun/2025
United Therapeutics USD 11.45 0.02 Jun/2025
Vertex Pharmaceuticals USD 27.81 3.5 Jun/2025